Mirum Pharmaceuticals MIRM made its public debut Thursday morning, opening at $13 after being priced at $15 per share.
The shares are listed on the Nasdaq and trading under the symbol MIRM.
Mirum Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases.
Citigroup, Evercore ISI and Guggenheim Securities are acting as joint book-running managers for the offering. Raymond James is acting as lead manager. Roth Capital Partners is acting as co-manager.
Related Links:
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
